~115 million common shares outstanding to ~175 million common shares outstanding. The 60 million share private placement is effectively a ~50% dilution. Not too surprising that the share price tanked a bit as the initial reaction. Let's see how the day plays out. I sure hope that there is another deal in the works that the Letter of Intent was referring to other than this. Like others have pointed out....we need cash for the planned renal and Fabry trials.....as well as other R&D/clinical endeavors. If there is another deal in the works that is contigent on the futility analysis, at least we have breathing room now to not absolutely need the FA to occur in Q4 (though I sure hope the FA happens sooner rather than later).

BearDownAZ